Infliximab effective in treatment of plaque-type psoriasis
As reported in the British Journal of Dermatology, of patients with plaque-type psoriasis (n=660) treated with infliximab (5 mg/kg) at weeks 0, 2, and 6, then q 8 weeks through week 50, 56.8% achieved PASI 75, 71.6% of whom maintained the response through week 98. Of patients who achieved PASI 75 by week 14, 64.7% maintained the response through week 50. Of patients who did not achieve PASI 75 by week 50, 66.3% achieved PASI 75 by week 98.
CTC count predicts survival in mBC
As reported in The Lancet Oncology, circulating tumor cell (CTC) quantification in patients (20 studies; n = 1944) with metastatic breast cancer (mBC) predicts progression-free survival (PFS) and overall survival (OS), especially when coupled with clinicopathologic data. A CTC count ≥ 5/7.5 mL at baseline is associated with decreased PFS (HR = 1.92) and OS (HR = 2.78). An elevated CTC count 3-5 weeks and 6-8 weeks after treatment commences is also associated with decreased PFS (HR = 1.85 and 2.20) and OS (HR = 2.26 and 2.91).
Apelin levels correlate with insulin sensitivity and lipid profile in PCOS
As reported in Seizure: European Journal of Epilepsy, patients with epilepsy (n=3182) have a 3-fold increased risk for cerebral stroke. The risk was highest in the 20-39 year age group and those taking high doses of anti-epileptic medications.